Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 7/20 | 0.38 |
| ▸ | CPT2 | P23786 | 6/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.37 |
| ▸ | CPT1B | Q92523 | 4/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166455 | 1.00 | CPT1A (0.38) | CPT1ACPT2USP30NAA50CPT1B | |
| SCHEMBL166175 | 0.90 | USP30 (0.38) | CPT1ACPT2USP30CPT1BTRPV1 | |
| SCHEMBL716617 | 0.90 | USP30 (0.38) | CPT1ACPT2USP30CPT1BTRPV1 | |
| SCHEMBL2713636 | 0.85 | TRPV1 (0.40) | CPT1ACPT2NAA50CPT1BTRPV1 | |
| SCHEMBL6466401 | 0.85 | TRPV1 (0.40) | CPT1ACPT2NAA50CPT1BTRPV1 | |
| SCHEMBL166997 | 0.85 | TRPV1 (0.43) | CPT1ACPT2NAA50CPT1BTRPV1 | |
| SCHEMBL166998 | 0.85 | TRPV1 (0.43) | CPT1ACPT2NAA50CPT1BTRPV1 | |
| SCHEMBL174020 | 0.84 | NAA50 (0.38) | CPT1ACPT2USP30NAA50CPT1B | |
| SCHEMBL174022 | 0.84 | NAA50 (0.38) | CPT1ACPT2USP30NAA50CPT1B | |
| SCHEMBL7872430 | 0.83 | TRPV1 (0.45) | CPT1ACPT2NAA50CPT1BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103079562-A | BACE inhibitors for use in the treatment of diabetes | HOFFMANN LA ROCHE | 2013-05-01 | — | — | CN | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | CPT1A 743/4885CPT2 624/4885USP30 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.